Early Treatment for Acute ACL Tear

• Status: Completed
• Trial end date: 2017-02-05
• Target enrollment: 0
• Participant gender: All

Summary

This research study is the first of its kind and will allow health care professionals and researchers to answer many questions about the reasons why anterior cruciate ligament (ACL) injury leads to knee pain and disability and osteoarthritis. We also hope that this study will be the beginning of new, more powerful and safer drugs to help patients with ACL injuries heal sooner and return to sports or daily activities pain free. Study participants will be recruited from the University of Kentucky and Vanderbilt University.

The purpose of this research is to gather information on how safe and effective Kenalog® is in alleviating knee pain following ACL rupture.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cale Jacobs; Christian Lattermann
• Collaborator: Vanderbilt University
• Treatments: Pharmaceutical Solutions; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• currently participating in sporting activities

• Normal contralateral knee status

• Anterior Cruciate Ligament (ACL) injury occurred while playing a sporting activity

Exclusion Criteria:

• underlying inflammatory disease (i.e. Rheumatoid Arthritis, Psoriatic Arthritis, etc.)

• have been diagnosed with hepatitis B or tuberculosis

• currently have an infection, including infection of the skin

• have a disease that weakens your immune system such as diabetes, cancer, HIV or AIDs

• other major medical condition requiring treatment with immunosuppressant or modulating drugs.

• A history of chronic use of non-steroidal anti-inflammatory drugs

• previous exposure or allergic reaction to Kenalog

• prior knee surgery (Ipsilateral or contralateral)

• have received any investigational drug with 4 weeks of study Visit 1